Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

European Electrotechnics will become part of OMZ Perspective Technologies Group

3/14/24 EELT

Cherkizovo shipped a large shipment of soybean oil to China

3/14/24 GCHE

X5 Retail Group launches 5Post.Market online store

3/14/24 X5

TCS Holding will present its long-term strategy by the end of the year

3/14/24 T

Shareholders of Diasoft approved dividends for 2023

3/14/24 DIAS

Fesco delivered the first shipment of bananas from India to Russia

3/14/24 FESH

TCS Holding launches buyback program

3/14/24 T

Tinkoff and merges with Rosbank

3/14/24 T

Rosbank merges with Tinkoff

3/14/24 ROSB

TCS Group reported for 2023 by IFRS

3/14/24 T